Sanofi
Fused pentacyclic imidazole derivatives as modulators of TNF activity

Last updated:

Abstract:

A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNF.alpha. activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

14 Mar 2018

Issue date:

23 Mar 2021